Arcutis Biotherapeutics (ARQT) said Wednesday it has acceded to a request by Padagis to stay a patent lawsuit over Arcutis' Zoryve cream 0.3% for plaque psoriasis.
As part of a joint stipulation agreement filed in court Wednesday, Arcutis said Padagis is required to report to Arcutis any correspondence from the US Food and Drug Administration regarding its abbreviated new drug application for a potential generic alternative to Zoryve.
The companies also agreed to extend the 30-month Hatch-Waxman stay of regulatory approval by one day for every day the litigation is stayed as of March 24, according to Arcutis.
Patent protection for Zoryve cream 0.3% extends until 2037, Arcutis said.
Shares of Arcutis were up more than 10% in recent trading.
Price: 16.54, Change: +1.56, Percent Change: +10.41
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.